reports
Coloplast A/S - Finanskalender 2025-26
Coloplast A/S - Finanskalender 2025-26 Venligst se vedlagte pdf. For yderligere information og kalenderinvitationer til kommende begivenheder, besøg venligst: Med venlig hilsen,Investor RelationsColoplast A/STel. 4911 1800 For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardKoncerndirektør, CFOTlf. 4911 1111 Kristine Husted MunkSenior Director, Investor RelationsTlf. 4911 1800 / 4911 3266E-mail: Simone Dyrby HelvindSenior Manager, Investor RelationsTlf. 4911 1800 / 4911 2981E-mail: Presse og medierPeter MønsterSr. Media Relations Manage...
Coloplast A/S - Financial Calendar 2025-26
Coloplast A/S - Financial Calendar 2025-26 Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: Kind regards,Investor RelationsColoplast A/STel. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSenior Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSenior Manager, Investor RelationsTel. / Email: Press and mediaPeter MønsterSr. Media Relations ManagerTel. Email: AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenm...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Kristof Samoy
CMB.Tech Unique & future proof industrial shipping platform
Late August CMB.TECH completed the merger with Golden Ocean which created one of the world's largest diversified listed maritime groups predominantly exposed to dry bulk (56% of GAV) and crude tankers (26% of GAV). Considering the ageing global tanker & bulker fleet, the group boosts an attractive low average vessel age and -thanks to its ongoing NB programme- still has room for further asset disposals while the future-proof vessels hold interesting optionality for low carbon fuel adoption. The ...
Novonesis and Novo Nordisk will explore new solutions to improve metab...
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. COPENHAGEN, Denmark – September 8, 2025. Novonesis and Novo Nordisk has entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The gut microbiome is the collection of microorganisms, such as bacteria, fungi, and viruses, that naturally live in the human gut. The science...
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye fi...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new fin...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030 In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-te...
- ING Helpdesk
REVISED VERSION - Benelux Morning Notes - updated to include IBA news
CFE: 1H results a bit light, FY outlook maintained. CMB.TECH: VLCC reasonable, pressure on Dry Bulk rates. dsm-firmenich: Givaudan CMD; Strategy 2030. Gimv: Investing in specialised healthcare services in the Netherlands. IBA: More sales but at lower margin
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
CMB.TECH announces Q2 2025 results
CMB.TECH announces Q2 2025 results CMB.TECH ANNOUNCES Q2 2025 RESULTSMERGER WITH GOLDEN OCEAN COMPLETED ANTWERP, Belgium, 28 August 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2025. HIGHLIGHTS Corporate highlights: CMB.TECH completed the merger with Golden Ocean on 20 AugustCMB.TECH is listed on NYSE (CMBT), EURONEXT Brussels (CMBT) and EURONEXT Oslo (CMBTO)Supervisory Board changes: resignation of Mr. Marc Saverys, appoint...
- ABGSC Financials Research
- Patrik Brattelius
PRESS RELEASE: Disclosure regarding a transparency notification - Arti...
PRESS RELEASE: Disclosure regarding a transparency notification - Article 14, 1st paragraph, of the Law of 2 May 2007 relating to the disclosure of important shareholdings in listed companies Antwerp, Aug. 27, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) received a transparency notification from Saverco NV on 25 Augustus 2025. Saverco NV has crossed below the transparency threshold of 65%. 1. Content of the notification from 25 August 2025 The notification dated 25 August 2025 contains the following information:...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.